A 6-Month, Double-Blind, Phase 2 Study and 6-Month Open- Label Extension Evaluating the Safety, Tolerability, and Clinical Benefit of RPh201 in Individuals With Alzheimer's Disease With or Without Coexisting Cerebrovascular Disease
Overview
- Phase
- Phase 2
- Intervention
- RPh201
- Conditions
- Mild to Moderate Dementia Due to Alzheimer's Disease
- Sponsor
- Regenera Pharma Ltd
- Enrollment
- 83
- Locations
- 5
- Primary Endpoint
- AEs at Month 6
- Status
- Completed
- Last Updated
- 6 years ago
Overview
Brief Summary
This study is a randomized, double-blind, placebo-controlled, multicentre, Phase 2 study, with an optional open-label extension, to evaluate the safety, tolerability, and efficacy of RPh201 in subjects with mild to moderate AD who are eligible for enrollment in this study.
Subject participation will include a Screening Phase, Treatment Phase, and an Optional Open-Label Extension. The Screening Phase will be up to 4 weeks prior to randomization. Both the subject and their study partner(s) will sign an informed consent form (ICF). At Visit 2, Subjects will be randomized 2:1 to RPh201 or placebo. The Treatment Phase will last for 6 months post-randomization, or until subject withdrawal from the study, whichever comes first. The Optional Open-Label Extension will begin once a subject has completed the Treatment Phase and the subject and their study partner(s) have signed an ICF to continue on the study. The Optional Open-Label Extension will continue for 6 months, or until subject withdrawal from the study, whichever comes first. Subjects who do not participate in the Optional Open-Label Extension will be asked to return for an optional post-study visit 6 months after the end of the Treatment Phase.
Subjects may participate in an optional biomarker sub-study. Up to 15 subjects may also participate in an optional FDG-PET sub-study during their study participation. Separate informed consent will be required for both of these sub-studies.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Subjects must be ≥65 years of age at the time of consent.
- •Subjects 65-69 years old, inclusive, must have evidence of cerebrovascular disease.
- •Meet National Institute on Aging-Alzheimer's Association 2011 criteria for All-Cause Dementia and have evidence for probable AD or possible AD with coexisting cerebrovascular disease. Coexisting cerebrovascular disease includes evidence of any of the following: cortical infarcts, subcortical and lacunar infarcts, macro or micro-hemorrhage, and small vessel ischemic microangiopathy.
- •Willing and able to provide informed consent or, if incapable of informed consent, have a legally authorized representative willing to consent on their behalf.
- •MMSE at screen visit: 15-22, inclusive.
- •Cholinesterase inhibitors, memantine, and other background medications impacting cognition and mood, if used, are at stable doses for at least 6 weeks prior to screening.
- •A study partner is available who has adequate contact with the subject to administer study drug, oversee study drug compliance, report on adverse events (AEs), and provide meaningful input into scales and assessments.
- •Adequate hearing, vision, and fluency in the language of testing.
- •Magnetic resonance imaging (MRI) of the brain must reveal findings consistent with AD with or without coexisting cerebrovascular disease. In subjects for whom brain MRI is contraindicated (e.g., presence of a pacemaker), computed tomography (CT) of the brain is acceptable. Historic MRI or CT scans up to 18 months prior to screening may be used for inclusion unless there have been interval clinical events warranting an updated scan.
- •Male subjects who are sexually active must agree to use one of the following acceptable methods of birth control from Screening and for at least one month after the last dose of study drug: abstinence (no sexual intercourse), male condom, or vasectomy.
Exclusion Criteria
- •Neurological or non-neurological conditions other than AD and cerebrovascular disease that, in the Investigator's opinion, contribute to, or provide alternative etiology for, the subject's dementia. Examples include, but are not limited to, brain tumors, clinically significant head injury, Parkinson's disease, current or prior excess use of alcohol that, in the investigator's judgment, has caused or significantly contributed to the subject's cognitive decline, or primary psychiatric disorders (e.g., schizophrenia or bipolar affective disorder).
- •Unstable medical conditions which are likely to impact subject's ability to complete the trial and which are likely to confound AE assessment. These include, but are not limited to, uncontrolled hypertension, uncontrolled diabetes, and cancer within past the 2 years. Exceptions include prostate cancer in-situ and local basal and squamous cell skin cancers.
- •Chronic use of systemic or inhaled steroids (use of topical steroids is acceptable).
- •Other concomitant medications that, in the Investigator's judgment, impair cognition and/or confound efficacy assessments.
- •Women of child-bearing potential are excluded (e.g., women who have not been post-menopausal for at least 2 years or are not surgically sterile).
- •Treatment with investigational product from a previous clinical drug trial within the last 30 days or five half-lives prior to Visit 2 (Baseline), whichever is longer.
Arms & Interventions
RPh201
A 26-week schedule consisting of twice-weekly subcutaneous administration of 400 μL of the IMP (20 mg RPh201).
Intervention: RPh201
Placebo
A 26-week schedule consisting of twice-weekly subcutaneous administration of 400 μL of the vehicle control.
Intervention: Placebo
Outcomes
Primary Outcomes
AEs at Month 6
Time Frame: Month 6
Clinical Laboratory Assessments - (blood and urine) at at Month 6
Time Frame: Month 6
Chemistry: alkaline phosphatase, albumin, blood urea nitrogen, calcium, chloride, creatinine, glucose (random), inorganic phosphorus, potassium, alanine aminotransferase, aspartate aminotransferase, gamma-glutamyl transpeptidase, lactate dehydrogenase, sodium, direct bilirubin, total bilirubin, total protein, amylase, uric acid Hematology: haemoglobin, hematocrit, red blood cell count, white blood cell (WBC) count, WBC differential (absolute counts), numerical platelet count Urinalysis: specific gravity, pH, ketones, glucose, nitrite, blood, leukocyte esterase, protein, urobilinogen, bilirubin If nitrite, blood, or protein tests are positive, a microscopic examination will be performed
Change in (Alzheimer disease assessment scale) ADAS-Cog score between Baseline and Month 6
Time Frame: Month 6
The ADAS-Cog is an established general cognitive measure scaled used in clinical trials of AD. The ADAS-Cog assesses multiple performance and cognitive domains including memory, language, praxis, and orientation. Test responses are scored using summed error points where 0 represents no errors and 70 represents errors on all items; higher scores indicate greater cognitive impairment.
Change in CDR-SB score between Baseline and Month 6
Time Frame: Month 6
The CDR is a global clinical scale with established diagnostic and severity-ranking utility widely used in clinical trials yielding global and sum of boxes scores (CDR-SB). The CDR global score is used in AD trials as a global measure of disease severity. The CDR is rated based on subject and informant input. The CDR assess three domains of cognition (memory, orientation, judgment/problem solving) and three domains of function (community affairs, home/hobbies, personal care) using semi- structured interviews of both the study subject and a companion/informant carried out by a trained rater and scored using a standard methodology. Each domain is rated on a 5-point scale of functioning as follows: (0) no impairment; (0.5) questionable impairment; (1) mild impairment; (2) moderate impairment; (3) severe impairment (personal care is scored on a 4-point scale without a 0.5 rating available). Higher scores indicate greater impairment.
Vital Signs
Time Frame: Month 6
Vital signs consist of tympanic temperature, respiratory rate, blood pressure (systolic and diastolic blood pressure, mmHg), and pulse (bpm) after at least 3 minutes rest. Blood pressure will be measured in a sitting or semi-reclined seated position. Weight and height will be captured at Screening and weight will be captured at all other visits where this assessment is performed.
12-lead ECG at Month 6
Time Frame: Month 6
Secondary Outcomes
- Change from Baseline on CDR-SB total scores at Month 12(Month 12)
- Change from Baseline in NPI total score at Month 6(Month 6)
- Change from Baseline on ADAS-Cog total scores at Month 5(Month 5)
- Change from Baseline on CDR-SB total scores at Month 3(Month 3)
- Change from Baseline in the MMSE at Month 3(Month 3)
- Change from Baseline in the MMSE at Month 6(Month 6)
- Change from Baseline in ADCS-ADL total score at Month 3(Month 3)
- Change from Baseline in NPI total score at Month 12(Month 12)
- Change from Baseline on ADAS-Cog total scores at Month 3(Months 3)
- Change from Baseline in NPI total score at Month 3(Month 3)
- Change from Baseline on ADAS-Cog total scores at Month 12(Month 12)
- Change from Baseline on CDR-SB total scores at Month 5(Month 5)
- Change from Baseline in ADCS-ADL total score at Months 12(Month 12)
- AEs at Month 12(Month 12)
- Clinically significant changes in vital signs at Month 12(Month 12)
- Vital Signs(Month 12)
- Clinical Laboratory Assessments - (blood and urine) at Month 12(Month 12)
- Change from Baseline in the MMSE at Month 12(Month 12)
- 12-lead ECG at Month 12(Month 12)